Abstract
MicroRNAs are a class of evolutionarily small non-coding RNAs of 19 to 25 nucleotides in length, that represent one of the most exciting areas of current medical science as they can regulate a complex regulatory network of gene expression and physiologic processes including differentiation, proliferation and apoptosis in a highly context dependent fashion. Recently, their role in cardiovascular disease and in the regulation of cardiomyocyte size and function, in the action potential, in angiogenesis and in mitochondrial function was recognized. Importantly, they have been evaluated for their prognostic and diagnostic role in heart failure and modification of specific microRNAs levels has been tested as a therapeutic option in experimental heart failure models. In this review article we refer the most emerging evidence, concerning the role of microRNAs in myocardial development in heart failure pathophysiology and prognosis, and their therapeutic implications.
Keywords: Biomarkers, heart failure, microRNA, myocardial hypertrophy, prognosis, treatment.
Current Topics in Medicinal Chemistry
Title:Diagnostic and Therapeutic Potentials of microRNAs in Heart Failure
Volume: 13 Issue: 13
Author(s): Evangelos Oikonomou, Gerasimos Siasos, Dimitris Tousoulis, Eleni Kokkou, Vasiliki Genimata, Konstantinos Zisimos, George Latsios and Christodoulos Stefanadis
Affiliation:
Keywords: Biomarkers, heart failure, microRNA, myocardial hypertrophy, prognosis, treatment.
Abstract: MicroRNAs are a class of evolutionarily small non-coding RNAs of 19 to 25 nucleotides in length, that represent one of the most exciting areas of current medical science as they can regulate a complex regulatory network of gene expression and physiologic processes including differentiation, proliferation and apoptosis in a highly context dependent fashion. Recently, their role in cardiovascular disease and in the regulation of cardiomyocyte size and function, in the action potential, in angiogenesis and in mitochondrial function was recognized. Importantly, they have been evaluated for their prognostic and diagnostic role in heart failure and modification of specific microRNAs levels has been tested as a therapeutic option in experimental heart failure models. In this review article we refer the most emerging evidence, concerning the role of microRNAs in myocardial development in heart failure pathophysiology and prognosis, and their therapeutic implications.
Export Options
About this article
Cite this article as:
Oikonomou Evangelos, Siasos Gerasimos, Tousoulis Dimitris, Kokkou Eleni, Genimata Vasiliki, Zisimos Konstantinos, Latsios George and Stefanadis Christodoulos, Diagnostic and Therapeutic Potentials of microRNAs in Heart Failure, Current Topics in Medicinal Chemistry 2013; 13 (13) . https://dx.doi.org/10.2174/15680266113139990104
DOI https://dx.doi.org/10.2174/15680266113139990104 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
The Application of Fungal Beta-glucans for the Treatment of Colon Cancer
Anti-Cancer Agents in Medicinal Chemistry Relationship Between Na<sup>+</sup>, K<sup>+</sup>-ATPase and NMDA Receptor at Central Synapses
Current Protein & Peptide Science Radiolabelled Oligonucleotides for Imaging of Gene Expression with PET
Current Medicinal Chemistry Donor-transmitted Anterior Myocardial Ischaemia in a Teenager: How to Proceed?
New Emirates Medical Journal Natural Products of Dietary Origin as Lead Compounds in Virtual Screening and Drug Design
Current Pharmaceutical Biotechnology Inhibiting Breast Cancer Progression by Exploiting TGFβ Signaling
Current Drug Targets Peripartum Cardiomyopathy: An Intriguing Challenge. Case Report with Literature Review
Current Cardiology Reviews Diabetic Cardiomyopathy and its Prevention by Metallothionein: Experimental Evidence, Possible Mechanisms and Clinical Implications
Current Medicinal Chemistry Remodeling of Protein Aggregates by Hsp104
Protein & Peptide Letters Hydroximic Acid Derivatives: Pleiotropic Hsp Co-Inducers Restoring Homeostasis and Robustness
Current Pharmaceutical Design Soluble Guanylate Cyclase Stimulators and Activators: Where are We and Where to Go?
Mini-Reviews in Medicinal Chemistry Mitochondrial Mutations in Atherosclerosis: New Solutions in Research and Possible Clinical Applications
Current Pharmaceutical Design Effect of Aging on Metabolic Pathways in Endothelial Progenitor Cells
Current Pharmaceutical Design Nitric Oxide Synthase and Cyclooxygenase Pathways: A Complex Interplay in Cellular Signaling
Current Medicinal Chemistry The Application of Angiotensin Converting Enzyme Inhibitors in Heart Surgery
Letters in Drug Design & Discovery Human Cognitive and Neuro-Psychiatric Bio-Markers in the Cardiac Peri-Operative Patient
Current Molecular Medicine Repurposing of Benzimidazole Scaffolds for HER2 Positive Breast Cancer Therapy: An <i>In-Silico</i> Approach
Current Drug Research Reviews Periostin as a Heterofunctional Regulator of Cardiac Development and Disease
Current Genomics Update in the Management of Diastolic Heart Failure
Current Vascular Pharmacology Curcumin Potentiates The Ability of Sunitinib to Eliminate the VHL-lacking Renal Cancer Cells 786-O: Rapid Inhibition of Rb Phosphorylation as a Preamble to Cyclin D1 Inhibition
Anti-Cancer Agents in Medicinal Chemistry